Overall market sentiment has been down on Iovance Biotherapeutics Inc (IOVA) stock lately. IOVA receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.
Iovance Biotherapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on IOVA!
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With IOVA Stock Today?
Iovance Biotherapeutics Inc (IOVA) stock is trading at $14.92 as of 12:34 PM on Thursday, Mar 28, a gain of $0.81, or 5.78% from the previous closing price of $14.10. The stock has traded between $14.10 and $15.18 so far today. Volume today is light. So far 2,370,385 shares have traded compared to average volume of 13,758,629 shares.
To see InvestorsObserver's Sentiment Score for Iovance Biotherapeutics Inc click here.
More About Iovance Biotherapeutics Inc
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma.
Click Here to get the full Stock Report for Iovance Biotherapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
